seekRNA Directs Precise Gene Insertion

Researchers have developed a new method for precise target selection by using unusual type DEDD transposases. The method, seekRNA, is based on the IS1111 and IS110 insertion sequences and can be reprogrammed to target different sites.

By: Gorm Palmgren - Jun. 25, 2024
News

The study reveals that members of the IS1111 and IS110 insertion sequence (IS) families use a noncoding RNA (NCR)-derived seekRNA to guide target site selection during transposition. This seekRNA, which copurifies with the DEDD transposase, contains sequences complementary to both strands of the target site, essential for transposition.

The seekRNA's configuration differs between the two families, indicating distinct mechanisms of target recognition. The researchers demonstrated the biotechnological potential of reprogramming the seekRNA and donor flank to target different sites, thereby enhancing gene-editing precision.

In experiments, the team showed that seekRNA's role is crucial for the transposition of both the IS element and any cargo it may carry, such as therapeutic genes. The researchers successfully reprogrammed seekRNAs to direct transposition to new target sequences, proving its versatility.

This approach presents a significant advancement in the field of genetic engineering, offering a method to achieve high specificity in gene insertion without introducing unintended mutations. The innovation could pave the way for more precise gene therapy applications, reducing the risk of off-target effects commonly associated with traditional gene-editing technologies.

The study was led by Ruth Hall and Sandro Ataide at the University of Sydney, Australia, and it was published in Nature Communications on June 19, 2024.

**CRISPRMED25 - The 2nd CRISPR Medicine Conference, Copenhagen, Denmark, April 8-11, 2025**

Learn about the latest discoveries in CRISPR Medicine at the CRISPRMED25 Conference in Copenhagen, Denmark, April 8-11, 2025.

Tags

HashtagArticleHashtagCMN BriefsHashtagNews

News: seekRNA Directs Precise Gene Insertion
CLINICAL TRIALS
Refractory Hypercholesterolemia, NCT06451770
Sponsors:
Verve Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Huntington's Disease, (NCT05032196)
Sponsors:
Wave Life Sciences Ltd.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine